Endothelin antagonists
US7208517B1 · kind B1 · utility
14Cited by
13References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 31, 2000 |
| Grant date | Apr 24, 2007 |
| Priority date | — |
| Expiry date | Jun 1, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/40
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound of the formula (I):or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, a method of antagonizing endothelin, methods for the inhibition of bone metastases, methods for the prevention of growth of new metastases, methods for the inhibition of bone turnover, and methods for the prevention of bone loss in patients, including cancer patients, using an endothelin ET-A receptor antagonist.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.